J&J Medical Connect
Immunology
Immunology

Congress Materials – Florida Society of Rheumatology (FSR 2026)

This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.

Achievement of DAPSA/cDAPSA Low Disease Activity With Guselkumab in Active and Erosive Psoriatic Arthritis Across Participant Subgroups in APEX

Christopher T Ritchlin, Laura C Coates, Philip J Mease, Alexa P Kollmeier, Weihong Hu, Soumya D Chakravarty, Stacey Fitch, Karissa Lozenski, Alexis Ogdie, Proton Rahman


This document will be available after July 17th 2026

APEX: Durable Inhibition of Structural Damage Progression and Improvements in Joint Disease Activity Over 48Weeks With Guselkumab in Active and Erosive Psoriatic Arthritis

Christopher T Ritchlin, Philip J Mease, Laura C Coates, Alexa P Kollmeier, Bei Zhou, Yusang Jiang, Karen Bensley, Koeun Im, Rattandeep Batra, Karissa Lozenski, Steven Fakharzadeh, Soumya D Chakravarty, Proton Rahman, Désirée van der Heijde


This document will be available after July 17th 2026

Efficacy and Safety of Guselkumab in Active Psoriatic Arthritis With Inadequate Response/Intolerance to One Prior TNF Inhibitor Through 1 Year of the SOLSTICE Study

Alice B Gottlieb, Joseph F Merola, Philip J Mease, Christopher T Ritchlin, Jose U Scher, Kimberly Parnell Lafferty, Soumya D Chakravarty, Yanli Wang, Yevgeniy Krol, Stacey Fitch, Alexis Ogdie


This document will be available after July 17th 2026

Guselkumab Response and Inhibition of Structural Damage Progression in Active Psoriatic Arthritis Across APEX Participant Subgroups

Philip J Mease, Christopher T Ritchlin, Laura C Coates, Alexa P Kollmeier, Bei Zhou, Yusang Jiang, Karen Bensley, Koeun Im, Rattandeep Batra, Karissa Lozenski, Soumya D Chakravarty, Proton Rahman, Désirée van der Heijde


This document will be available after July 8th 2026

Icotrokinra in Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: Pooled Analysis of the Phase 3 ICONIC-LEAD, ICONIC-ADVANCE 1, and ICONIC-ADVANCE 2 Trials

Iain B. McInnes, Linda Stein Gold, Robert Bissonnette, Mark G. Lebwohl, Ofelia Reyes-Servin, Joseph Cafone, Ya-Wen Yang, Soumya D. Chakravarty, Charles Iaconangelo, Shu Li, Tasneam Shagroni, Karissa Lozenski, April W. Armstrong, Joseph F. Merola


This document will be available after July 17th 2026

Real-World On-Label Treatment Persistence Through 24 Months in Biologic-Naïve and Biologic-Experienced Patients with PsA: Guselkumab versus tsDMARDs

Philip J Mease, Jessica Walsh, Timothy P Fitzgerald, Soumya D. Chakravarty, Elizabeth Adamson, Pavithra Srinivas, Bruno Emond, Arthur Voegel, Yuxi Wang, Sinia Sareen, Helena Huang, Patrick Lefebvre, Dominic Pilon, Shikha Singla, Joseph F Merola


This document will be available after July 17th 2026

 

Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.

J&J Medical Connect

Connect with us

Connect with us

Would you like to clear and leave your conversation? Message history will be lost.